Glenmark Pharma to use IFC's $40 mn loan for debt refinance and capex
Pharma major Glenmark Pharmaceuticals Ltd will be utilising the $40 million loan from International Finance Corporation (IFC) to refinance existing debt and for capital expenditure.
image for illustrative purpose
Chennai, April 6 Pharma major Glenmark Pharmaceuticals Ltd will be utilising the $40 million loan from International Finance Corporation (IFC) to refinance existing debt and for capital expenditure.
Glenmark is having a good presence in generics, over the counter and specialty drugs.
The IFC has committed an unsecured loan of $40 million to the company.
Queried about the deployment of the loan fund a company spokesperson told IANS: "The $40 mn loan will be utilized to refinance existing Foreign Currency Convertible Bonds (FCCBs) and capex funding."
The IFC in 2016 had invested in convertible debt of $75 million in Glenmark for expansion project.
According to the Glenmark spokesperson, IFC had subscribed to the company's FCCB for a principal of $75 million.
"The FCCB's have maturity in June 2022 and are not yet converted," the official said.
